Contact: Sal Braico
(608)441-2890
sbraico@conjugon.com
FOR IMMEDIATE RELEASE
November 29, 2004, Madison, WI- ConjuGon, a biotechnology company developing
fundamentally new treatments for antibiotic-resistant bacterial infections,
announced today that it has appointed Guillermo Herrera to its Board of
Directors.
Mr. Herrera spent more than 24 years with Abbott Laboratories where his
positions included Senior Vice President of International Operations,
President of Abbott International. Mr. Herrera held other senior leadership
positions, including Vice President, European Operations, and Vice
President, Latin American and Canada Operations. He was elected an Abbott
Corporate Vice President in 1996. Mr. Herrera currently is a Principal of
the Rosetta Group, LLC (Lake Forest, Illinois), a biotechnology investment
fund.
“Guillermo has great insights and expertise from his years working in
proprietary pharmaceuticals,” said ConjuGon CEO Christopher Price. “His
experience in all aspects of pharmaceutical development, operations and
marketing will be invaluable assets for ConjuGon. The ConjuGon Board of
Directors, the management team, and I all look forward to working closely
with Guillermo as we continue to develop our technology.”
“The problem of antibiotic resistance is getting worse and worse every
day,” stated Mr. Herrera. “Fundamentally new technologies are critically
needed to overcome a serious public health threat. I’m excited about
working with ConjuGon in helping it bring new health care solutions to
patients.”
ConjuGon is developing fundamentally new technologies to combat the growing
epidemic of antibiotic-resistant bacteria. Antibiotic resistance is a
medical crisis, globally responsible for hundreds of thousands of deaths
each year. ConjuGon’s core technology is a new way to kill multi-drug
resistant bacteria. The company is located in the MG&E Innovation Center in
Madison, Wisconsin.
